MedTrace Logo

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

NCT04023721 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2020-07-22

No results posted yet for this study

Summary

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.

Conditions

Interventions

DRUG

Inarigivir soproxil

Inarigivir soproxil 200 mg tablets

DRUG

Nucleoside/nucleotide (NUC) analogue inhibitors

Continuation of prestudy NUC therapy

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • F-star Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Don Mitchell · Spring Bank Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-18
Primary Completion
2020-07-16
Completion
2020-07-16

Countries

  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04023721 on ClinicalTrials.gov